General
Preferred name
Semaglutide
Synonyms
Ozempic ()
P&D ID
PD076099
CAS
910463-68-2
Tags
available
drug
Drug Status
investigational
approved
Drug indication
Type-2 diabetes
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Semaglutide is a glucagon like peptide 1 (GLP-1) receptor peptidomimetic agonist . Structurally it is a modified analogue of with amino acids at positions 8 and 34 replaced by α-aminobutyric acid and arginine respectively, and Lys26 is acylated with stearic diacid. Semaglutide has slightly lower GLP-1 receptor affinity than , but this is compensated by an increased serum albumin affinity, which ensures improved resistance to metabolic degradation. (GtoPdb)
Compound Sets
7
AdooQ Bioactive Compound Library
A18908
DrugBank
DB13928
DrugBank Approved Drugs
DB13928
DrugMAP
DMAGFOD
DrugMAP Approved Drugs
DMAGFOD
Guide to Pharmacology
9724
Natural product-based probes and drugs
External IDs
13
Properties
(calculated by RDKit )
Molecular Weight
4111.12
Hydrogen Bond Acceptors
56
Hydrogen Bond Donors
57
Rotatable Bonds
149
Ring Count
6
Aromatic Ring Count
6
cLogP
-11.63
TPSA
1646.18
Fraction CSP3
0.61
Chiral centers
30.0
Largest ring
6.0
QED
0.01
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Biosynthetic Origin
Peptide (Ribosomal)
Therapeutic Indication
Antidiabetic
Therapeutic Class
Metabolic Disorders
Source data